Inhibiting mutant FGFR2 in endometrial cancer by extracellular blockade

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1011301

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Endometrial cancer is a common gynecological cancer in women and new therapies are required to improve survival rates. We have identified mutations in a key cell membrane protein (FGFR2) and shown that endometrial cancer cells with these mutations have altered growth factor dependence. Inhibiting these mutant proteins can result in cell death. By characterizing these mutations and their cellular effects we will be able to develop specific blocking agents for use as potential novel treatments

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2013

Funding Scheme: NHMRC Project Grants

Funding Amount: $354,859.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Cell Biology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer cell biology | cancer therapy | endometrial cancer | fibroblast growth factor receptors (FGFR) | molecular mechanisms

Related Links